RESUMO
Cimetidine induces reversible dose-related central nervous system (CNS) toxicity. Trough serum concentrations and the development of CNS toxicity correlate. We compared cimetidine kinetics in 12 healthy subjects and 31 patients. Six of the latter had normal renal and liver function, five had renal disease only, 12 had liver disease only, and eight had both renal and liver disease. Postmortem tissue distribution was assessed in 11 patients, and expressed as tissue:serum ratio. Average cimetidine total clearance (ClB) in milliliters per minute for each group was as follows: patients with renal and liver disease (182 +/- 105), renal disease only (193 +/- 24), liver disease only (463 +/- 145), normal patients (510 +/- 93), and healthy subjects (583 +/- 140). Renal function was the major determinant for ClB, and the relationship was described by ClB = 4.2(CCr) + 140, r = 0.87, where CCr is creatinine clearance. Cimetidine clearance was affected little by age. Tissue:serum ratios from highest to lowest were as follows: kidney greater than stomach greater than liver greater than bone greater than brain greater than fat. Central and steady-state distribution volumes were not influenced by age or disease. There was enchanced CNS penetration in liver disease patients; their cerebrospinal fluid (CSF):serum ratio was twice the normal. Our kinetic studies identify patient characteristics likely to result in elevated blood levels, and suggest that the greatest risk of CNS toxicity is in those with liver disease.
Assuntos
Doença Crônica/metabolismo , Cimetidina/metabolismo , Guanidinas/metabolismo , Adolescente , Adulto , Fatores Etários , Idoso , Barreira Hematoencefálica , Cimetidina/líquido cefalorraquidiano , Meia-Vida , Humanos , Taxa de Depuração Metabólica , Pessoa de Meia-Idade , Distribuição TecidualRESUMO
The postabsorptive distribution of cimetidine is described. Assays by high pressure liquid chromatography (HPLC) of postmortem samples of cerebrospinal fluid, serum, and solid tissues were used to determine pharmacokinetic parameters as well as mean tissue: serum concentration (T:S) ratios in seven patients with renal and liver dysfunction. Correlations were calculated between the T:S ratio and the volume of distribution, and between the T:S concentration ratio and the time of sampling after death. The highest T:S ratios occurred in the eliminating organs, the liver and kidneys, and the lowest in fat. As the time of autopsy increased after death, the T:S ratios decreased.
Assuntos
Cimetidina/análise , Tecido Adiposo/metabolismo , Adulto , Idoso , Autopsia , Cimetidina/sangue , Cimetidina/líquido cefalorraquidiano , Cimetidina/metabolismo , Feminino , Humanos , Rim/metabolismo , Nefropatias/metabolismo , Cinética , Fígado/metabolismo , Hepatopatias/metabolismo , Masculino , Pessoa de Meia-Idade , Distribuição TecidualAssuntos
Encéfalo/efeitos dos fármacos , Cimetidina/toxicidade , Guanidinas/toxicidade , Idoso , Barreira Hematoencefálica , Cimetidina/líquido cefalorraquidiano , Confusão/induzido quimicamente , Feminino , Humanos , Falência Renal Crônica/metabolismo , Masculino , Pessoa de Meia-Idade , Convulsões/induzido quimicamenteRESUMO
The pharmacokinetics and cerebrospinal fluid (CSF) partitioning of cimetidine were studied in the dog. Four healthy male mongrel dogs were given a 22 mg/kg iv dose of cimetidine. The dogs demonstrated metabolic and pharmacokinetic characteristics similar to human volunteers, as the total body clearance of cimetidine averaged 7.5 ml/min/kg in the dog as compared to 7.7 ml/min/kg in humans. Autopsy tissue concentrations were similar to those measured in humans. There were no statistical differences between dogs and humans in any pharmacokinetic parameters. Cimetidine sulfoxide was the major metabolite in the dog, similar to that in humans. Cimetidine CSF partitioning, as determined by the ratio of cimetidine CSF:serum area under the curve was 0.125 +/- 0.03. Cimetidine appears to enter the CSF by passive diffusion, and is removed by passive diffusion, CSF bulk flow, and possibly by an active transport process. We conclude that the dog is an appropriate animal to investigate cimetidine pharmacokinetics and is a suitable model for examining the CSF uptake of H2-antagonists.
Assuntos
Cimetidina/líquido cefalorraquidiano , Animais , Barreira Hematoencefálica , Cimetidina/sangue , Cães , Infusões Parenterais , Cinética , Masculino , Distribuição TecidualRESUMO
Cimetidine, a histamine H2 receptor antagonist, is known to have some effects on central nervous system, and is reported to emerge in the cerebrospinal fluid (CSF). We evaluated the elimination of cimetidine from CSF by the method of ventriculo-cisternal perfusion in rats. The extraction ratio of cimetidine at the low perfusate concentration (14 nM) was 0.190 +/- 0.023 (n = 3), while that significantly (p less than 0.02) decreased to 0.0916 +/- 0.081 (n = 3) at the high concentration (4 mM). No significant difference was observed in the production rate of CSF between these two concentrations. These findings suggest that cimetidine is excreted from CSF to blood by a saturable transport system.
Assuntos
Cimetidina/metabolismo , Animais , Transporte Biológico , Cimetidina/sangue , Cimetidina/líquido cefalorraquidiano , Masculino , Perfusão , Ratos , Ratos Endogâmicos , TrítioRESUMO
The major goal of this study was to develop a small animal model that could be used to assess quantitatively the clearance of cimetidine from the cerebrospinal fluid (CSF) under relatively physiologic conditions. In addition, we addressed questions related to the pathways involved in the elimination of cimetidine from the CSF. We administered high and low bolus doses of cimetidine together with inulin, as a marker of bulk flow, into the lateral ventricle of anesthetized rats and sampled CSF from the cisterna magna. Principles of linear pharmacokinetic systems were applied to the data to obtain clearances from the CSF. The clearance of inulin was 2.02 +/- 0.22 microliters/min, which is in excellent agreement with the CSF production rate of 2.2 microliters/min in anesthetized rats. The clearance of cimetidine from the CSF following the administration of a low dose was 11.8 +/- 3.1 microliters/min, which is in good agreement with the cimetidine CSF clearance in the rat obtained previously in studies using the technique of ventriculocisternal perfusion. A 32% decrease in the CSF clearance of cimetidine (P less than 0.05) was observed when the high dose was administered, suggesting that CSF elimination is saturable. The clearance of inulin was unaffected by the high dose of cimetidine. This study demonstrates that the technique of lateral ventricle injection and sampling from the cisterna magna is useful in quantitatively assessing the elimination of compounds from the CSF in the rat under relatively physiologic conditions.
Assuntos
Cimetidina/líquido cefalorraquidiano , Animais , Biotransformação , Cimetidina/metabolismo , Inulina , Masculino , Ratos , Ratos EndogâmicosRESUMO
1 Thirty-six patients with various neurological diseases or symptoms received single intravenous doses of either cimetidine 400 mg (n = 19) or oxmetidine 200 mg (n = 17), 15 or 60 min before a diagnostic lumbar puncture. 2 In the 15 min CSF samples concentrations of cimetidine were detectable but not measurable in 5 and non-detectable in 3 patients. 3 In the 60 min CSF samples the concentrations of cimetidine were detectable in all 11 patients and were measurable in 8 of these patients with a mean +/- s.e. mean of 0.12 +/- 0.01 microgram/ml. These CSF concentrations were correlated to simultaneously measured plasma concentrations (P less than 0.01). The mean ratio CSF/plasma concentration was 0.03. 4 No detectable concentrations of oxmetidine were found either in the 15 min (n = 9) or in the 60 min (n = 8) liquor samples. 5 Cimetidine penetrates the blood-drain barrier slowly and not freely after a single dose. Our data suggest that the new histamine H2-receptor antagonist oxmetidine does not cross this barrier.
Assuntos
Cimetidina/líquido cefalorraquidiano , Guanidinas/líquido cefalorraquidiano , Imidazóis/líquido cefalorraquidiano , Adulto , Idoso , Cimetidina/administração & dosagem , Feminino , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória , Fatores de TempoRESUMO
Following a recent report that epithelial cells of the choroid plexus possess histamine H2 receptors, the effect of cimetidine and ranitidine, histamine H2 receptor antagonists, on the secretion and electrolyte content of CSF was examined. Fifty cats were divided into one control (n = 6) and six experimental groups. CSF was collected by puncture of the cisterna magna following pentobarbital anesthesia, and its volume, concentrations of Na+, K+, Cl-, and pH were determined. Cimetidine or ranitidine (50, 20, or 10 mg/kg) was injected intravenously 2 h after the start of the test, and their concentrations were measured in hourly blood samples and in 30-min aliquots of CSF in the 50 mg/kg experimental groups. Whereas the secretion of CSF did not change over 6 h in the control group, it decreased significantly by 30-60 min after injection of cimetidine or ranitidine and remained low for the following 6 1/2 h in all experimental groups except the 10-mg ranitidine group. Peak cimetidine and ranitidine concentrations in CSF in the 50-mg experimental groups were noted 60 and 90 min, respectively, after intravenous injection. CSF electrolyte concentrations and pH did not change during the test in any group. We conclude that intravenous cimetidine or ranitidine can significantly reduce CSF secretion in the cat, possibly by competitive inhibition of the histamine effect on H2 receptors located on the choroid plexus epithelial cell, or by a direct effect on the capillaries of the choroid plexus.
Assuntos
Líquido Cefalorraquidiano/metabolismo , Cimetidina/farmacologia , Antagonistas dos Receptores H2 da Histamina/farmacologia , Ranitidina/farmacologia , Animais , Gatos , Cloretos/líquido cefalorraquidiano , Cimetidina/sangue , Cimetidina/líquido cefalorraquidiano , Relação Dose-Resposta a Droga , Concentração de Íons de Hidrogênio , Potássio/líquido cefalorraquidiano , Ranitidina/sangue , Ranitidina/líquido cefalorraquidiano , Sódio/líquido cefalorraquidianoRESUMO
A patient with severe liver disease and mildly obnormal but stable renal function was given cimetidine on two occasions for gastrointestinal hemorrhage. In each course, dosing was initiated at half the recommended dosage of 600 mg daily, and mental status deteriorated shortly after dosing began. A further dosage decrease to 300 mg daily allowed continuation of cimetidine therapy in absence of mental status alterations. In this patient, mental status changes occurred at lower serum concentrations than we have previously reported. This discrepancy was explained by analysis of cimetidine CSF concentrations, as this patient had abnormally high cimetidine blood to CSF permeability. Although the cause of increased CSF concentrations is unclear, cimetidine-associated mental confusion was dose related and completely reversible upon a decrease in dosage. Patients who develop cimetidine-associated mental status changes and who cannot have treatment stopped may be safely treated by individualizing the dosing rate.
Assuntos
Cimetidina/efeitos adversos , Transtornos Cognitivos/induzido quimicamente , Confusão/induzido quimicamente , Hemorragia Gastrointestinal/tratamento farmacológico , Guanidinas/efeitos adversos , Barreira Hematoencefálica , Cimetidina/sangue , Cimetidina/líquido cefalorraquidiano , Relação Dose-Resposta a Droga , Varizes Esofágicas e Gástricas/complicações , Varizes Esofágicas e Gástricas/etiologia , Feminino , Hemorragia Gastrointestinal/etiologia , Humanos , Cirrose Hepática Biliar/complicações , Pessoa de Meia-IdadeRESUMO
15 cases of cimetidine-associated mental confusion have been reported. In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes. These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05). The severity of M.S. changes increased as trough-concentrations rose, 5 patients had lumbar puncture. The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system. Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction. They should be closely observed and should be given reduced doses of cimetidine.